trending Market Intelligence /marketintelligence/en/news-insights/trending/oPNJYZIDBT5OFrw8Tdtu1g2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Dr. Reddy's plaque psoriasis treatment secures US approval

Blog

Banking Essentials Newsletter - February Edition

Blog

Message in a (Word)Cloud

Six trends shaping the industries and sectors we cover in 2021

Six trends shaping the industries and sectors we cover in 2021


Dr. Reddy's plaque psoriasis treatment secures US approval

The U.S. Food and Drug Administration approved Dr. Reddy's Laboratories Ltd.'s new drug application for Impoyz cream for the treatment of moderate to severe plaque psoriasis in patients 18 years of age or older.

Impoyz is licensed to Encore Dermatology Inc. for commercialization of the product in the U.S.